Design Therapeutics (NASDAQ:DSGN – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.02, FiscalAI reports.
Design Therapeutics Stock Performance
NASDAQ DSGN traded down $0.52 during trading on Thursday, hitting $10.11. The stock had a trading volume of 84,841 shares, compared to its average volume of 582,926. The company has a market capitalization of $632.75 million, a PE ratio of -8.58 and a beta of 1.73. The company’s 50-day moving average price is $12.36 and its two-hundred day moving average price is $12.14. Design Therapeutics has a 12 month low of $6.23 and a 12 month high of $17.25.
Wall Street Analyst Weigh In
A number of analysts have weighed in on DSGN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Design Therapeutics in a report on Thursday, October 15th. Wells Fargo & Company assumed coverage on shares of Design Therapeutics in a report on Friday, October 2nd. They set an “overweight” rating and a $26.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.86.
View Our Latest Stock Report on DSGN
Design Therapeutics Company Profile
Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.
The company’s research has focused on disorders affecting the nervous system, muscles and eyes.
See Also
- Five stocks we like better than Design Therapeutics
- The Fed Is Split on Rates—Why These 2 Treasury ETFs Could Have an Edge
- Gold’s 2026 Pullback Raises a Bigger Question: Buy the Metal or the Miners?
- Matador Resources Insider Buying and the Case for a Dividend Stock Rebound
- Datadog’s Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight?
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}